{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:09:17Z","timestamp":1761919757686},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejca.2013.11.030","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T22:00:22Z","timestamp":1387576822000},"page":"793-800","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing"],"prefix":"10.1016","volume":"50","author":[{"given":"R.","family":"Kastner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Preuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pr\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Niklas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Foskett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.11.030_b0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2013.11.030_b0010","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0015","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quintas-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2013.11.030_b0020","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.11.030_b0025","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0035","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ejca.2013.11.030_b0040","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0045","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","article-title":"High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations","volume":"21","author":"Vivante","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0050","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.97","article-title":"Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)","volume":"22","author":"Preuner","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2013.11.030_b0060","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1038\/leu.2008.180","article-title":"Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR","volume":"22","author":"Pelz-Ackermann","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","article-title":"BCR-ABL1 kinase domain mutations: methodology and clinical evaluation","volume":"87","author":"Alikian","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2013.11.030_b0070","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0075","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2013.11.030_b0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0085","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3324\/haematol.2012.068890","article-title":"The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2013.11.030_b0090","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2011.08.015","article-title":"Quantitative monitoring of BCR\/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia","volume":"48","author":"Preuner","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.11.030_b0100","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/leu.2011.187","article-title":"Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients","volume":"26","author":"Gruber","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-2105-14-176","article-title":"Routine performance and errors of 454 HLA exon sequencing in diagnostics","volume":"14","author":"Niklas","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ejca.2013.11.030_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0120","first-page":"692","article-title":"Dissecting the complexity of Philadelphia-positive mutated populations by ultra-deep sequencing of the Bcr-Abl kinase domain: biological and clinical implications","volume":"120","author":"Soverini","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2013.11.030_b0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.leukres.2008.08.024","article-title":"Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on \u201cA recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients\u201d by Curvo et al. [Leuk. Res.]","volume":"33","author":"Cho","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.11.030_b0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.leukres.2007.04.018","article-title":"A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients","volume":"32","author":"Curvo","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.11.030_b0135","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","article-title":"A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib","volume":"20","author":"Gruber","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2013.11.030_b0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","article-title":"An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy","volume":"10","author":"Laudadio","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2013.11.030_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000210060","article-title":"BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors","volume":"121","author":"Ma","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ejca.2013.11.030_b0150","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","article-title":"The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"118","author":"O\u2019Hare","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.11.030_b0155","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","article-title":"Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia","volume":"22","author":"Sherbenou","year":"2008","journal-title":"Leukemia"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T22:55:49Z","timestamp":1538952949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913010265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0959804913010265"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}